Sensorion announces positive clinical results for hearing loss therapies SENS-501 and SENS-401 at the World Congress of Audiology on September 20, 2024.
Sensorion, a clinical-stage biotech firm focused on hearing loss therapies, announced positive clinical results for its SENS-501 and SENS-401 programs at the World Congress of Audiology on September 20, 2024. CEO Nawal Ouzren emphasized the company's advancements in innovative treatments aimed at restoring and preventing hearing loss. Additionally, Sensorion has released its Half Year 2024 Report, detailing its financial performance, accessible on their website.
September 23, 2024
3 Articles